Episode Details
Back to Episodes
Could One Extra Injection Make Glaucoma Surgery Last Longer? New Evidence Points to Better Trabeculectomy Success
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/could-one-extra-injection-make-glaucoma-surgery-last-longer-new-evidence-points-to-better-trabeculectomy-success
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Could One Extra Injection Make Glaucoma Surgery Last Longer? New Evidence Points to Better Trabeculectomy Success Evidence reviewed through August 30, 2026 Introduction Trabeculectomy remains one of the most powerful operations for lowering eye pressure in advanced or progressing glaucoma. It can reduce eye pressure to levels that are difficult to achieve with eye drops, laser treatment, or many newer minimally invasive procedures. Its main weakness is scarring. After surgery, the body may treat the new drainage pathway as an injury that needs to be repaired. Fibroblasts move into the area, collagen is deposited, and the filtering bleb can become thick, flat, or sealed. When that happens, the operation may gradually lose its effect. A new long-term report suggests that a single intravitreal injection of bevacizumab given during trabeculectomy, in addition to mitomycin C, may substantially improve the chance that the operation remains medication-free three years later. The reported difference is striking: 92.3% medication-free success with bevacizumab plus mitomycin C 71.2% medication-free success with mitomycin C alone Absolute difference: approximately 21 percentage points Approximate number needed to treat: 5 patients The result is important, but it is not yet enough to conclude that every patient undergoing trabeculectomy should receive the injection. The trial was relatively small, took place at one center, involved a largely European-ancestry population, and has not yet been independently reproduced with the same technique. The Short Answer The new evidence is promising and biologically plausible, and it is stronger than most earlier studies of anti–vascular endothelial growth factor treatment during trabeculectomy. However, the evidence currently supports the following conclusion: > Intravitreal bevacizumab may be a useful adjunct to mitomycin C in selected trabeculectomy patients, but it is not yet established routine care. The apparent benefit seems to come mainly from better control of the early postoperative wound-healing response, rather than from permanently lowering eye pressure by itself. The injection produced larger, less inflamed blebs early after surgery, and this early advantage was associated with fewer medications and fewer failures later. The next step should be larger, independent, multicenter trials with more diverse patients and at least five years of follow-up. What the New Randomized Trial Actually Found Study design and patient population The study was the three-year follow-up of the Bevacizumab in Trabeculectomy Study, conducted at a single tertiary ophthalmic center in South Australia. It included adults with progressing glaucoma for which the treating surgeon believed trabeculectomy was necessary. Participants could undergo: Primary trabeculectomy Redo trabeculectomy Trabeculectomy combined with cataract surgery A total of 131 patients were randomized: 65 patients received bevacizumab 66 patients received placebo The bevacizumab group received 1.25 milligrams in 0.05 milliliters by intravitreal injection at the end of trabeculectomy. The control group received an intravitreal injection of balanced salt solution. Both groups also received trabeculectomy with mitomycin C. The surgical protocol used: Mit